単位用量製造の世界市場：市場規模・シェア・動向分析 (調達方法別・製品別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

単位用量製造市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の単位用量製造の市場規模は2030年までに1,506億1,000万米ドルに達し、2025年から2030年までのCAGRは11.43%を記録すると予測されています。

2020年前半、市場の成長は停滞していましたが、2020年末には回復に転じました。これは主に、COVID-19の治療に単位用量が使用され、同じボトルから用量を取り扱ったり注いだりする際のリスクが減少したためです。

単位用量製剤には、薬剤が容易に識別でき、投与時まで薬剤の製剤が保護されるという多くの利点があります。容器が無傷で薬剤が未使用の場合、製剤を変更することなく再処分・回収することができます。最も重要な利点は、適切な量を投与することができ、患者が規定の限度を超えないようにできることです。

しかし、COVID-19の大流行は医薬品市場に大きな影響を与えています。COVID-19パンデミックの前半は成長が鈍化しましたが、2020年末には市場が回復し始めました。単位用量製造は、取り扱いや汚染のリスクを低減するため、現在のシナリオでは有利に使用されています。また、単位用量は、空気感染や直接触れることによるウイルス感染の可能性を排除するため、患者とヘルスケア従事者の両方を保護するために、COVID-19患者用の病院で広く使用されています。

単位用量製造市場レポートハイライト

• 調達方法別では、アウトソーシング部門が2024年の収益市場シェア60.74%で最大となり、市場をリードしました。アウトソーシングサービスは、費用対効果、専門知識、柔軟性、リスク軽減、世界市場へのアクセスなどの理由で、単位用量製造業界を支配しました。
• 固形単位用量セグメントは、2024年に50.49%の最大売上シェアで市場をリードしました。錠剤やカプセルのような固形単位投与剤形は、その高い需要、広範な用途、患者の利便性により、単位投与マーケティングを支配しています。
• 最終用途別では、独立薬局部門が2024年に39.11%の最大収益シェアで市場をリードし、予測期間中のCAGRも最速と予測されます。
• 北米は2024年に37.73%の最大収益シェアで単位用量製造市場を独占しました。同地域の高度な医療インフラ、慢性疾患の高い有病率、患者の安全性と投薬の正確性に焦点を当てた強い規制が、市場収益の成長を牽引しています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 単位用量製造市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 技術の情勢
• 価格モデル分析
• 市場分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 単位用量製造市場：調達方法別の推定・動向分析

• セグメントダッシュボード
• 単位用量製造市場：調達方法別の変動分析
• 調達先別 (2018～2030年)
• 社内
• アウトソーシング

第5章 単位用量製造市場：製品別の推定・動向分析

• セグメントダッシュボード
• 単位用量製造市場：製品別の変動分析
• 製品別 (2018～2030年)
• 液体単位用量
• 固形単位用量
• その他

第6章 単位用量製造市場：最終用途別の推定・動向分析

• セグメントダッシュボード
• 単位用量製造市場：最終用途の変動分析
• 最終用途別 (2018～2030年)
• 独立薬局
• 長期介護施設
• 病院
• その他

第7章 単位用量製造市場：地域別の推定・動向分析

• 市場シェア分析：地域別 (2024年・2030年)
• 市場ダッシュボード：地域別
• 世界市場のスナップショット：地域別
• 北米
  • 市場推計・予測、
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 市場推計・予測、
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • スウェーデン
  • デンマーク
  • ノルウェー
• アジア太平洋
  • 市場推計・予測、
  • 日本
  • 中国
  • インド
  • タイ
  • 韓国
  • オーストラリア
• ラテンアメリカ
  • 市場推計・予測、
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 市場推計・予測、
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業分類
  • 市場リーダー
  • 新興企業
• 企業市況分析、2024年 (企業ヒートマップ分析)
• 企業プロファイル
  • Catalent Inc.
  • Unither Pharmaceuticals
  • Thermo Fisher Scientific
  • Corden Pharma
  • Mikart
  • Tape Mark
  • Renaissance Lakewood LLC
  • Medical Packaging Inc
  • American Health Packaging
  • PCI Pharma Services
  • Amcor PLC
  • Bristol-Myers Squibb
  • AbbVie Inc.
  • Merck &Co. Inc.
  • Pfizer Inc.

List of Tables

• Table. 1 Market segmentation
• Table. 2 Market research process
• Table. 3 Information procurement
• Table. 4 Primary research pattern
• Table. 5 Market research approaches
• Table. 6 Value chain-based sizing & forecasting
• Table. 7 QFD modelling for market share assessment
• Table. 8 Market formulation & validation
• Table. 9 Unit dose manufacturing market revenue, 2018 - 2030 (USD Million)
• Table. 10 Unit dose manufacturing market snapshot
• Table. 11 Unit dose manufacturing market driver impact
• Table. 12 Unit dose manufacturing market restraint impact
• Table. 13 Unit dose manufacturing sourcing key takeaways (USD Million)
• Table. 14 Unit dose manufacturing market: Sourcing movement analysis
• Table. 15 In-house market, 2018 - 2030 (USD Million)
• Table. 16 Outsourcing market, 2018 - 2030 (USD Million)
• Table. 17 Unit dose manufacturing market product key takeaways (USD Million)
• Table. 18 Unit dose manufacturing market: Product movement analysis
• Table. 19 Liquid unit dose market, 2018 - 2030 (USD Million)
• Table. 20 Solid unit dose market, 2018 - 2030 (USD Million)
• Table. 21 Others market, 2018 - 2030 (USD Million)
• Table. 22 Unit dose manufacturing market end use key takeaways (USD Million)
• Table. 23 Unit dose manufacturing market: End use movement analysis
• Table. 24 Independent pharmacies market, 2018 - 2030 (USD Million)
• Table. 25 Long term care facility market, 2018 - 2030 (USD Million)
• Table. 26 Hospitals market, 2018 - 2030 (USD Million)
• Table. 27 Others market, 2018 - 2030 (USD Million)
• Table. 28 Regional marketplace: Key takeaways
• Table. 29 Regional outlook, 2024 & 2030
• Table. 30 North America unit dose manufacturing Market, 2018 - 2030 (USD Million)
• Table. 31 U.S. unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 32 Canada unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 33 Mexico unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 34 Europe unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 35 UK unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 36 Germany unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 37 France unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 38 Italy unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 39 Spain unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 40 Sweden unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 41 Denmark unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 42 Norway unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 43 Asia Pacific unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 44 Japan unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 45 China unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 46 India unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 47 Thailand unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 48 South Korea unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 49 Australia unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 50 Latin America unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 51 Brazil unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 52 Argentina unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 53 Middle East & Africa unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 54 South Africa unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 55 Saudi Arabia unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 56 UAE unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 57 Kuwait unit dose manufacturing market, 2018 - 2030 (USD Million)
• Table. 58 Market participant categorization

List of Figures

• Fig. 1 List of Tables
• Fig. 2 List of Secondary Sources
• Fig. 3 List of Abbreviations
• Fig. 4 Global Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 5 Global Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 6 Global Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 7 Global Unit Dose Manufacturing, by Region, 2018 - 2030 (USD Million)
• Fig. 8 North America Unit Dose Manufacturing, by Country, 2018 - 2030 (USD Million)
• Fig. 9 North America Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 10 North America Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 11 North America Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 12 U.S. Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 13 U.S. Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 14 U.S. Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 15 Canada Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 16 Canada Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 17 Canada Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 18 Mexico Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 19 Mexico Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 20 Mexico Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 21 Europe Unit Dose Manufacturing, by Country, 2018 - 2030 (USD Million)
• Fig. 22 Europe Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 23 Europe Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 24 Europe Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 25 Germany Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 26 Germany Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 27 Germany Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 28 UK Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 29 UK Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 30 UK Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 31 France Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 32 France Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 33 France Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 34 Italy Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 35 Italy Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 36 Italy Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 37 Spain Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 38 Spain Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 39 Spain Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 40 Denmark Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 41 Denmark Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 42 Denmark Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 43 Sweden Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 44 Sweden Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 45 Sweden Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 46 Norway Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 47 Norway Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 48 Norway Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 49 Asia Pacific Unit Dose Manufacturing, by Country, 2018 - 2030 (USD Million)
• Fig. 50 Asia Pacific Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 51 Asia Pacific Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 52 Asia Pacific Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 53 China Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 54 China Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 55 China Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 56 Japan Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 57 Japan Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 58 Japan Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 59 India Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 60 India Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 61 India Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 62 South Korea Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 63 South Korea Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 64 South Korea Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 65 Australia Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 66 Australia Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 67 Australia Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 68 Thailand Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 69 Thailand Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 70 Thailand Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 71 Latin America Unit Dose Manufacturing, by Country, 2018 - 2030 (USD Million)
• Fig. 72 Latin America Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 73 Latin America Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 74 Latin America Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 75 Brazil Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 76 Brazil Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 77 Brazil Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 78 Argentina Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 79 Argentina Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 80 Argentina Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 81 Middle East & Africa Unit Dose Manufacturing, by Country, 2018 - 2030 (USD Million)
• Fig. 82 Middle East & Africa Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 83 Middle East & Africa Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 84 Middle East & Africa Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 85 South Africa Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 86 South Africa Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 87 South Africa Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 88 Saudi Arabia Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 89 Saudi Arabia Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 90 Saudi Arabia Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 91 UAE Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 92 UAE Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 93 UAE Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)
• Fig. 94 Kuwait Unit Dose Manufacturing, by Sourcing, 2018 - 2030 (USD Million)
• Fig. 95 Kuwait Unit Dose Manufacturing, by Product, 2018 - 2030 (USD Million)
• Fig. 96 Kuwait Unit Dose Manufacturing, by End Use, 2018 - 2030 (USD Million)

Unit Dose Manufacturing Market Growth & Trends:

The global unit dose manufacturing market size is expected to reach USD 150.61 billion by 2030, registering a CAGR of 11.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. In the first half of 2020, the growth of the market was stagnant, but the market started to recover by the end of 2020. It was mainly due to the use of unit doses for the treatment of COVID-19 as it decreases the risk involved while handling and pouring doses from the same bottle.

Unit dose manufacturing has many advantages as the drug can be easily identified, and the formulation of the drug is protected until the moment of administration. If the container is intact and the drug has not been used, it can be redisposed and retrieved without changing its formulation. The most important benefit is that it can be administered in the proper dosage and ensures that the patient does not exceed the prescribed limit.

However, the COVID-19 pandemic has a significant effect on the pharmaceutical market. The first half of the COVID-19 pandemic had slowed growth but by the end of 2020, the market started to recover. The unit dose manufacturing is lucratively used in the current scenario as it reduces the risk of handling and contamination. Also, unit doses are widely used in hospitals for COVID-19 patients to safeguard both patients and healthcare personnel to eliminate the possibility of viral transmission by airborne transmission or direct touch.

Unit Dose Manufacturing Market Report Highlights:

• By sourcing, the outsourcing segment led the market with the largest revenue market share of 60.74% in 2024. Outsourcing services dominated the unit dose manufacturing industry, owing to cost-effectiveness, expertise, flexibility, risk reduction, and access to global markets.
• The solid unit dose segment led the market with the largest revenue share of 50.49% in 2024. Solid unit dosage forms such as tablets and capsules dominate unit dose marketing due to their high demand, widespread applications, and patient convenience.
• Based on end use, the independent pharmacies segment led the market with the largest revenue share of 39.11% in 2024 and is also anticipated to register at the fastest CAGR over the forecast period.
• North America dominated the unit dose manufacturing market with the largest revenue share of 37.73% in 2024. The market revenue growth is driven by the region's advanced healthcare infrastructure, high prevalence of chronic diseases, and strong regulatory focus on patient safety and medication accuracy.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates And Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Unit Dose Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increased Adoption of Unit Doses
    • 3.2.1.2. Benefits of Manufacturing Unit Doses Over Repackaging
    • 3.2.1.3. Growing Outsourcing Activities
    • 3.2.1.4. Technological Advancements in Unit Dose Manufacturing
    • 3.2.1.5. Increasing Prevalence of Chronic Diseases and Demand for Personalized Medicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Challenges Associated with the Adoption of Manufactured Unit Doses
    • 3.2.2.2. Compliance Issues with Outsourcing
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Unit Dose Manufacturing Market: Sourcing Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Unit Dose Manufacturing Market: Sourcing Movement Analysis
• 4.3. Unit Dose Manufacturing Market Estimates & Forecasts, by Sourcing, 2018 - 2030 (USD Million)
• 4.4. In-House
  • 4.4.1. In-House Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 4.5. Outsourcing
  • 4.5.1. Outsourcing Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Unit Dose Manufacturing Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Unit Dose Manufacturing Market: Product Movement Analysis
• 5.3. Unit Dose Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
• 5.4. Liquid Unit Dose
  • 5.4.1. Liquid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 5.5. Solid Unit Dose
  • 5.5.1. Solid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Unit Dose Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Unit Dose Manufacturing Market: End Use Movement Analysis
• 6.3. Unit Dose Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
• 6.4. Independent Pharmacies
  • 6.4.1. Independent Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 6.5. Long Term Care Facility
  • 6.5.1. Long Term Care Facility Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 6.6. Hospitals
  • 6.6.1. Hospitals Market Estimates & Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Unit Dose Manufacturing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Thailand
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Australia
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Catalent Inc.
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Unither Pharmaceuticals
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Thermo Fisher Scientific
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Corden Pharma
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Mikart
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Tape Mark
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Renaissance Lakewood LLC
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Medical Packaging Inc
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. American Health Packaging
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. PCI Pharma Services
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Amcor PLC
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Bristol-Myers Squibb
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. AbbVie Inc.
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Financial Performance
    • 8.3.13.3. Service Benchmarking
    • 8.3.13.4. Strategic Initiatives
  • 8.3.14. Merck & Co. Inc.
    • 8.3.14.1. Company Overview
    • 8.3.14.2. Financial Performance
    • 8.3.14.3. Service Benchmarking
    • 8.3.14.4. Strategic Initiatives
  • 8.3.15. Pfizer Inc.
    • 8.3.15.1. Company Overview
    • 8.3.15.2. Financial Performance
    • 8.3.15.3. Service Benchmarking
    • 8.3.15.4. Strategic Initiatives